Posts tagged blood-brain barrier
IntelGenx initiates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (OTCQX:IGXT; TSXV:IGX) has initiated the Phase 2a proof-of- concept clinical trial with its Montelukast VersaFilm in Alzheimer’s disease patients, following clearance by Health Canada. 

Read More
IntelGenx’s montelukast featured on Alzaforum

An article on the Alzaforum website highlights IntelGenx (OTCQX:IGXT; TSXV:IGX) and its montelukast oral film candidate for the treatment of brain degenerative diseases, such as early-stage dementia.

Read More
Ladenburg starts Reata at buy

Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12.

Read More
IntelGenx has positive pilot study with montelukast film

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has completed a pilot clinical study for montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference product.

Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer’s disease.

Read More